Novo Nordisk Expands Ozempic Access in Canada as Buyback and HSBC Upgrade Propel Rally, Though Overbought Signals Sound Caution
Veröffentlicht: 07.07.2026 um 14:13 Uhr, Redaktion boerse-global.de
Novo Nordisk’s stock is riding a multi-week recovery, powered by a steady share buyback and a strategic move to broaden access to its blockbuster diabetes drug Ozempic in Canada. Yet the rally has pushed technical indicators into overbought territory, and analysts remain divided on whether the rebound has further to run.
The Danish pharma group reported on Tuesday that it repurchased 1 million B-shares between June 29 and July 3, bringing total buybacks since the programme commenced in February to 23,009,179 B-shares. The repurchases are conducted under EU Safe Harbour rules and form part of a broader 15 billion Danish kroner framework that runs through February 2027. Novo Nordisk now holds 40,194,480 of its own B-shares, equivalent to roughly 0.9% of its share capital. The continued buyback sends a clear signal of management’s confidence in the company’s valuation.
Alongside the buyback, Novo Nordisk is widening access to Ozempic in Canada. Starting July 6, 2026, patients with private insurance will be eligible for discounted prices under an expanded savings programme, which was previously limited to those paying out of pocket. The initiative, which covers all of Canada except Quebec, aims to align Ozempic’s price with that of generic alternatives. Iain Graham, the company’s Canada chief, said the programme is designed to give all patients fair access to their preferred therapy. Ozempic, whose active ingredient semaglutide is used by more than 1 million Canadians, received Health Canada approval in 2018.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
On the analyst front, HSBC has raised its price target for Novo Nordisk from 280 to 300 Danish kroner, a move that comes amid the current recovery phase. The stock closed at 43.06 euros on Monday, according to the secondary source, but by Tuesday had risen to 43.90 euros, a gain of 1.53% on the day and nearly 23% over the past month. However, not all analysts share HSBC’s optimism. A separate rating places the stock at "Hold" with a target of just $42 — essentially flat to the current price. Critics point to a weak outlook for 2026 and growing pricing and reimbursement pressure in the GLP-1 market, arguing that these headwinds could cap further upside.
The rapid ascent has left the shares technically stretched. The 14-day relative strength index stands at 71.4, firmly in overbought territory, and the stock now trades more than 12% above its 50-day moving average of 39.06 euros — a sign that the rally has been concentrated in a short period. The annualised 30-day volatility reads 31.47%.
Despite the recent surge, Novo Nordisk’s stock is still down 1.75% year-to-date and nearly 26% over the past twelve months. It remains roughly 28% below its record high of 61.20 euros set in July 2025. The recovery from the March trough of 30.25 euros — a 42% rebound — has been fuelled by the buyback and the Canada access expansion, but the combination of overbought conditions and analyst caution suggests the months ahead could be more turbulent. The company’s half-year results will be the next major test of whether this rally rests on solid fundamental ground or is merely a technical counter-move after a difficult year.
Ad
Novo Nordisk Stock: New Analysis - 7 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
